Author Affiliations: Department of Neurology (Drs Nasir, Kerr, and Birnbaum), and Division of Rheumatology, Department of Medicine (Dr Birnbaum), The Johns Hopkins University School of Medicine, Baltimore, Maryland.
To describe the case of a patient with systemic lupus erythematosus (SLE) and neuromyelitis optica (NMO) who experienced 19 recurrent attacks of myelitis.
An outpatient neurorheumatology clinic at the Johns Hopkins Hospital devoted to care of patients with neurological manifestation of rheumatic diseases.
A woman with NMO and SLE.
Main Outcome Measures
Clinical and neuroimaging features of relapsing disease.
Recurrent and increasingly severe myelitis attacks still occurred after treatment with rituximab.
It may be progressively more difficult to prevent relapses and commensurate disability in patients with later stages of relapsing NMO. Recognition of NMO as a distinct diagnostic entity in patients with SLE and other rheumatic diseases is crucial, in that institution of earlier targeted immunosuppressant treatment may be more effective than later targeted immunosuppression. The cellular arm of the immune system may be recruited by pathogenic B cells and may explain why relapses may occur after treatment with B cell–depleting therapy.
Neuromyelitis Optica (NMO) is a devastating syndrome characterized by recurrent attacks of myelitis as well as optic neuritis.1,2 In recent years, there has been increasing evidence that the NMO-IgG autoantibody may have pathogenic as well as diagnostic relevance.3 There is also tantalizing, although circumstantial, evidence that NMO is mediated by perturbations in other parts of the humoral immune system.4,5
Approximately 85% of cases of NMO are relapsing.6 We describe the case of a patient with NMO and systemic lupus erythematosus (SLE) who, remarkably, had 19 attacks of myelitis. To our knowledge, this represents the highest number of myelitis attacks ever reported in a patient with NMO and provides a unique fulcrum for understanding the polyphasic course of NMO. The last 2 attacks occurred after treatment with rituximab, an anti-CD20 monoclonal antibody that leads to functional depletion of B cells. In this study, we propose that ongoing B-cell stimulation may have led to activation of the cellular arm of the immune system during earlier attacks and contributed to treatment intractability to rituximab during later attacks. Potential mechanisms of cellular-mediated autoimmunity in relapsing NMO are discussed. Our case suggests that treatments limited to B-cell depletion may not adequately address the potential role played by derangements in the cellular immune system, which, our case suggests, may be especially important during successive episodes of relapsing disease.
A 48-year-old, right-handed, African American woman had been diagnosed with SLE in 1996 (temporally referenced as year 0) when she presented with high-titer antinuclear antibody positivity, malar rash, photosensitivity, oral ulcers, and polyarthritis. After receiving of 400 mg of hydroxychloroquine per day, she had no further inflammatory symptoms or signs affecting her skin or joints.
In year 3, she developed her first attack of longitudinally extensive transverse myelitis (LETM), and from years 3 through 6 developed 3 further attacks of myelitis. All of the myelitis attacks satisfied the diagnostic criteria proposed by the Transverse Myelitis Consortium Working Group.7 She developed paraparesis and numbness below a clearly demarcated midthoracic sensory level, with T2-weighted and T1 postgadolinium imaging reportedly revealing LETM that affected the ventral part of the middle to lower thoracic cord. These inaugural attacks were characterized predominantly by sensory symptoms, with intact antigravity strength at nadir (Medical Research Council) 4 to 4+/5, and minimal urinary urge incontinence. She was treated with 1 g of methylprednisolone. After these attacks, she returned to her complete baseline without any functional impairment. Significantly, all of these inaugural (as well as later) attacks of myelitis occurred in the context of quiescent SLE activity; there was no further malar rash, photosensitivity, oral ulcers, arthralgia/arthritis, shortness of breath, serositis, hematuria, or sicca symptoms.
From year 7 through year 9, she suffered her 5th through 13th attacks of myelitis. Again, each of these attacks satisfied the criteria proposed by the Transverse Myelitis Consortium Working Group.7 There were clearly demarcated, rostral sensory levels ranging between T1 and T6. Associated with her 5th attack, she developed bilateral optic neuritis with bilateral loss of visual acuity to less than 20/400. She was treated for optic neuritis with 1 g of methylprednisolone for 5 days and recovered to her visual baseline within 3 months. However, she had worsening morbidity with successive myelitis attacks. In contrast to earlier attacks (1st through 4th attacks), these (5th through 13th) featured more significant motor and sphincteric dysfunction. From her 9th attack onward she had loss of antigravity strength at clinical nadir. Although successive attacks were associated with more protracted time to recovery, she still had interictal ability to walk without any ambulatory assist devices.
Each attack was treated with pulse corticosteroids. Because her lupus was quiescent, she was not maintained on immunosuppressant treatment. However, after her 13th attack she started an oral regimen of 75 mg of cyclophosphamide daily. After several months, she developed leiomyosarcoma of the bladder. Despite the abbreviated course of treatment, because of iatrogenic concerns, the cyclophosphamide was discontinued. She underwent cystectomy, and did not have radiation or chemotherapy.
Within a few months of cystectomy, in year 10, she developed her 14th attack of myelitis. In year 11, in the context of a urinary tract infection, she developed her 15th attack. This latter attack was distinguished by its acuity and severity, with rapid progression to complete paraplegia within 12 hours. Magnetic resonance imaging (MRI) revealed a T2-hyperintense, longitudinally extensive lesion extending from T3 through T10 (Figure 1A). Postgadolinium T1 sequences demonstrated a heterogeneous and patchy pattern of enhancement (Figure 1B). Brain MRI findings were normal. She was then referred to the Johns Hopkins Neuro-Rheumatology Clinic for further evaluation.
Magnetic resonance image (MRI) of the thoracic spine during the 15th attack of melitis. A, Sagittal T2-weighted MRI of the spine demonstrates patchy hyperintensities (arrow) from T3 through T10. B, Sagittal T1-weighted MRI with gadolinium contrast shows a patchy and heterogeneous pattern of enhancement most prominently at T9 and T10 (arrow).
On neurological examination, visual acuity was 20/40 bilaterally. Bilateral optic disc pallor was noted. On motor examination, she had spasticity in both lower extremities, with sustained clonus at both ankles. She had Medical Research Council power of 4 to 4+/5 in proximal muscle groups. Reflexes were 3 and symmetric in the upper extremities, 3+ at the patellars with crossed adductors, and plantar stimulation revealed upgoing toes. Sensory examination demonstrated an incomplete pin-prick level to T6. Laboratory tests revealed normal complements, with no evidence of antiphospholipid antibodies.
Because of recurrent LETM and bilateral optic neuritis, we suspected a diagnosis of NMO. The NMO-IgG autoantibody test was positive. Treatment with rituximab was recommended. Before this was approved by her insurance company, over the next 4 months in year 12, she suffered her 16th and 17th attacks of myelitis. She was given 1 g of methylprednisolone intravenously for 3 days and recovered to baseline deficits elicited in the above neurological examination. She ultimately received 2 doses of 1 g of rituximab, given 2 weeks apart, after she had recovered from her 17th attack.
Three months after receiving her second dose of rituximab, she suffered her 18th attack. She was again treated with 1 g of methylprednisolone. One month later, she suffered her 19th attack. Unfortunately, after the 19th attack, she was completely paraplegic and after 3 months has not recovered any motor strength. The MRI after this 19th attack revealed fusiform expansion of the thoracic cord, with LETM hyperintensity seen on sagittal T2-weighted MRI extending from T5 through T8 (Figure 2A) and a heterogenous pattern of enhancement from T7 through T9 (Figure 2).
Magnetic resonance imaging (MRI) of the thoracic spine during the 19th attack of myelitis, 4 months after rituximab treatment. A, Sagittal T2-weighted MRI of the spine demonstrates scattered hyperintense lesions from T5 through T8 (arrow) and a more continuous, longitudinally extensive hyperintensity from T8 through T10 (arrowhead). B, Sagittal T1-weighted MRI of the spine with gadolinium contrast demonstrates a heterogeneous pattern of enhancement from T7 through T9 (arrow).
After 5 months of rituximab therapy, peripheral flow cytometry has documented ongoing CD19 and CD20 cell depletion.
We present a case of a patient with NMO and SLE who had 19 recurrent attacks of myelitis. Our case is unique in several respects. First, the number of myelitis attacks is the most ever reported in the literature. Additionally, our patient developed a flurry of ongoing myelitis attacks, even after treatment with rituximab. Below, we provide key mechanistic and therapeutic implications of our case report, which may be useful in understanding the relentlessly polyphasic course of NMO.
Although initially considered a monophasic syndrome, it is now appreciated that NMO can be relentlessly polyphasic in approximately 85% of cases.8 In more than 50% of cases, patients with NMO may progress to functional blindness or wheelchair dependence within 5 years of index attacks.8 Our patient's cumulative disability was intimately associated with the frequency of relapsing attacks. Our case highlights the need for understanding why NMO can be polyphasic and for instituting treatments that may arrest further relapses.
There is intriguing, although circumstantial, evidence that the humoral arm of the immune system is the primary area associated with NMO.9 The NMO-IgG targets the aquaporin 4 antigen, the chief water-pump channel protein in the central nervous system.9 The binding of the aquaporin 4 antigen on astocytic foot processes colocalizes with sites of immunoglobulins and complement neoantigen deposition, suggesting a crucial role of NMO-IgG in participating and amplifying a humorally mediated response.9
Based on the orthodoxy that NMO is mediated by perturbations in the humoral immune system, studies have investigated the efficacy of rituximab in NMO.10,11 Rituximab targets the CD20 antigen appearing in the earliest and latest lineages of B cells.12 Open-label studies have shown reduction in frequency of relapses as well as functional improvement.10- 12 Prior to starting rituximab, our patient suffered 17 relapses. Nevertheless, after treatment with rituximab, she experienced 2 further attacks of myelitis, with MRI revealing gadolinium-enhancing lesions. Tragically, these last 2 attacks led to irreversible loss of antigravity strength in the lower extremities and culminated in wheelchair dependence.
We believe that our patient's unresponsiveness to rituximab, with clinical attacks corroborated by gadolinium-enhancing lesions, suggests that relapsing NMO may have broader immunologic mechanisms than currently appreciated. Hypothesized mechanisms concerning the role of B cells in NMO have mainly centered around the pathogenic role of NMO-IgG autoantibody in the context of the humoral arm of the immune system.9 In comparison, there has been less consideration given to the possibility that ongoing activation of B cells, especially in the context of recurrent myelitis attacks, may lead B cells to become potent antigen-presenting cells and therefore cause propagating damage in NMO due to perturbations in the cellular immune system.
Although B cells are inefficient as antigen-presenting cells,13 with increasing activation—as might be seen with recurrent attacks of LETM in NMO—they may display immunophenotypical features of competent antigen-presenting cells (ie, upregulation of CD40 and B7/B28).14 Antigens presented by B cells may be wholly different from cognate antigens recognized by the T-cell receptor. The endocytic processing of captured antigens may lead to different peptide sequences presented at the B cell–T cell immunologic synapse, leading to epitope spreading. This mechanism of epitope drift may diversify the range of salient epitopes that may lead to propagation of relapsing attacks. Such “kindling” of the immune system may suggest why a subset of patients with NMO may present with such ruthlessly relapsing NMO disease.
Therefore, we propose that, although the humoral arm of the immune system may play a crucial role in the initial attacks of NMO, recurrent attacks may cause the cellular arm of the immune system to mediate ongoing inflammation and damage in NMO. Our patient's devastating debility from her last 2 attacks, which tragically resulted in complete wheelchair dependence, occurred despite treatment with rituximab. This supports our hypothesis that relapsing NMO may not be exclusively mediated by the humoral arm of the immune system.
Although myelitis may be a manifestation of SLE,15 our patient's syndrome of NMO occurred in the context of quiescent lupus disease. Especially in patients with SLE and quiescent systemic SLE disease, the presence of clinical or serologic features suggestive of NMO represents the manifestation of a distinct, coincidental autoimmune disease. We have recently suggested that the American College of Rheumatology Classification Criteria for lupus neuropsychiatric syndromes be revised to include mandatory evaluation for NMO-IgG autoantibody in patients with features consistent with NMO.16
In conclusion, we present a patient with SLE and NMO who had 19 distinct episodes of recurrent myelitis, the most ever described in the literature. Our patient's relapsing course continued even after treatment with rituximab and suggests that pleiotropic mechanisms that cause perturbations in cellular as well as humoral immune responses may be crucial during relapsing attacks.
Correspondence: Julius Birnbaum, MD, MHS, Division of Rheumatology, Department of Medicine, Division of Neuroimmunology, Department of Neurology, The Johns Hopkins University School of Medicine, 5200 Eastern Ave, Mason F. Lord Building, Center Tower, Ste 4100, Baltimore, MD 21224 (email@example.com).
Accepted for Publication: November 20, 2008.
Author Contributions:Study concept and design: Kerr and Birnbaum. Acquisition of data: Nasir, Kerr, and Birnbaum. Drafting of the manuscript: Nasir. Critical revision of the manuscript for important intellectual content: Kerr and Birnbaum. Administrative, technical, and material support: Nasir. Study supervision: Kerr and Birnbaum.
Financial Disclosure: None reported.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 13
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.